Articles

Results 1 to 4 of 4


Director compensation limits and considerations

USA - May 8 2018 A recent ruling by the Delaware Supreme Court could have far-reaching consequences for how companies set their director compensation limits. Dentons'…

Victor H. Boyajian, Sahar A. Shirazi

SEC adopts final rules for securities crowdfunding under Title III of the JOBS Act

USA - December 3 2015 The US Securities and Exchange Commission (SEC) has adopted Regulation Crowdfunding, a series of rules that implements the provisions of Title III of…

Steven L. Berson, Walter Van Dorn, Margaret H. Kavalaris, Brian Lee, Stafford Matthews

Supreme Court rejects statistical significance requirement in 10b-5 action involving life science company's failure to disclose adverse event reports

USA - April 4 2011 On March 22, 2011, the Supreme Court of the United States issued an important opinion for life sciences companies in Matrixx Initiatives, Inc., et. al. v. Siracusano et. al., a class action securities lawsuit involving Matrixx's leading product, Zicam Cold Remedy.

Jeffrey A. Baumel

$1 billion available for emerging growth life sciences companies through health care reform

USA - April 12 2010 The recently enacted landmark health care reform legislation, H.R. 3590, the Patient Protection and Affordable Care Act, appropriates up to $1 billion in tax credits and cash grants for small and mid-sized life sciences companies to defray the costs of investment in qualifying therapeutic discovery projects undertaken in 2009 and 2010.

Jeffrey A. Baumel, Victor H. Boyajian, L. Robert Guenthner, Bret Koplow